$PEN News

Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)

Penumbra Wins FDA Clearance For Lightning CAVT Technology To Treat Deep Vein Thrombosis, Backed By BOLT-DVT Trial Results

Penumbra (PEN) Clinical Data Puts Its Valuation Back In Focus

New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism

Penumbra Presents Results From Subset Analysis Of STORM-PE Randomized Controlled Trial At Vascular InterVentional Advances Meeting

TFX vs. PEN: Which Stock Is the Better Value Option?

TFX or PEN: Which Is the Better Value Stock Right Now?

Incuvate Files Patent Infringement Lawsuit Against Penumbra

TFX vs. PEN: Which Stock Is the Better Value Option?

Penumbra, Inc. Reports Second Quarter 2026 Financial Results

Penumbra Q2 EPS $0.88 Misses $1.20 Estimate, Sales $390.046M Beat $389.009M Estimate

Penumbra (PEN) Following THUNDERBOLT Debut, Is The Stock A Bargain Or Fairly Valued

Penumbra (PEN) Wins FDA Clearance For THUNDERBOLT After Strong Stroke Study

THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care

First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke

Penumbra Initiates FORWARD Trial To Collect Safety, Efficacy Data On Mechanical Thrombectomy

Evercore ISI Group Maintains Outperform on Penumbra, Lowers Price Target to $320

GMED vs. PEN: Which Stock Should Value Investors Buy Now?

Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain?

Penumbra’s Thunderbolt approval poised to accelerate neuro thrombectomy innovation